Update on rifampin and rifabutin drug interactions

被引:102
作者
Baciewicz, Anne M. [1 ]
Chrisman, Cary R. [2 ]
Finch, Christopher K. [3 ,4 ]
Self, Timothy H. [3 ,4 ]
机构
[1] Johns Hopkins Bayview Med Ctr, Dept Pharm, Baltimore, MD USA
[2] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Methodist Univ Hosp, Memphis, TN 38163 USA
关键词
rifampin; rifabutin; drug interactions;
D O I
10.1097/MAJ.0b013e31814a586a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant interactions demonstrated by recent reports include everolimus, atorvastatin, rosiglitazone/pioglitazone, celecoxib, clarithromycin, caspofungin, and lorazepam. To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Studies and cases of rifampin drug interactions continue to increase rapidly. This review is a timely reminder to clinicians to be vigilant.
引用
收藏
页码:126 / 136
页数:11
相关论文
共 70 条
[1]  
Ahn HC, 2003, INT J TUBERC LUNG D, V7, P587
[2]   Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS [J].
Ayudhya, DPN ;
Thanompuangseree, N ;
Tansuphaswadikul, S .
CLINICAL PHARMACOKINETICS, 2004, 43 (11) :725-732
[3]   RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) :1667-1671
[4]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH ;
BEKEMEYER, WB .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (03) :565-568
[5]   Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites [J].
Backman, JT ;
Lulurila, H ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :154-167
[6]   Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome p450 inhibitors: A case report [J].
Bhaloo, S ;
Prasad, GVR .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) :2449-2451
[7]   Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide [J].
Bidstrup, TB ;
Stilling, N ;
Damkier, P ;
Scharling, B ;
Thomsen, MS ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (02) :109-114
[8]   Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects [J].
Bolton, AE ;
Peng, B ;
Hubert, M ;
Krebs-Brown, A ;
Capdeville, R ;
Keller, U ;
Seiberling, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :102-106
[9]  
BORCHARD U, 1990, CLIN PHYSIOL BIOCH, V8, P28
[10]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS .2. [J].
BORCHERDING, SM ;
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :711-716